Genetronics Biomedical (GEB) Presenting At DNA Vaccines Forum 
10/19/2005 5:13:03 PM

SAN DIEGO--(BUSINESS WIRE)--March 16, 2005--Genetronics Biomedical Corporation (AMEX:GEB), a late stage developer of oncology and other therapies using electroporation to deliver drugs and nucleic acids, announced today that Iacob Mathiesen, PhD, Executive Director, Gene Delivery, will make a presentation, by invitation, at the DNA Vaccines Forum in London, England, on March 18th, 2005, at 15:05 GMT. The theme of the forum is "How to Enhance the Safety and Potency of DNA Vaccines." Dr. Mathiesen will present data supporting the safety and enhanced efficacy of electroporation to deliver DNA plasmids into skeletal muscle of large animals. "Based upon data derived from pre-clinical studies, our electroporation technology has demonstrated that, using less DNA, it can induce immune responses earlier and that are of higher magnitude and greater durability compared to DNA plasmids alone," said Avtar Dhillon, MD, Genetronics' president and CEO. "We are pleased to present these results to this forum of industry leaders in DNA vaccination."